PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 8, 2026European Stroke Journal0 citationsOpen Access

Abstract Number: Esoc2026a600 Systematic Review and Descriptive Analysis of Therapeutic Approaches for Tissue-Filler Related Vision Loss Due to Arterial Occlusions

View Full Paper
AVAnna Vargas-VerdaguerAQAina QuinACAdrián Valls Carbó

Key Points

  • This analysis aims to evaluate the effectiveness of hyaluronidase and thrombolysis for treating tissue-filler related visual loss due to arterial occlusions.
  • Systematic search on PubMed and Scopus for reports on tissue-filler related visual loss.
  • Included studies must report visual acuity before and after treatment, with individual patient data extracted when available.
  • Visual outcomes were compared between patients treated with hyaluronidase or thrombolysis and those who received no treatment.
  • Visual improvement was observed in 36% of 76 affected eyes after treatment.
  • No significant difference in visual improvement was found between patients treated with hyaluronidase (63%) and those who were not (37%).
  • Similarly, visual improvement was not significantly different between thrombolytic treatment (15%) and no treatment (85%).

Abstract

Abstract Background and aims Tissue-filler related visual loss (TFRVL) due to retinal arterial occlusions represents an uncommon but serious complication of these procedures. We aimed to identify the effectiveness of hyaluronidase and thrombolysis for TFRVL through systematic review and descriptive analysis. Methods A systematic search on PubMed and Scopus identified reports of TFRVL. The protocol was registered with PROSPERO (CRD42022355129). Studies reporting visual acuity (VA) after TFRVL (baseline VA) and VA after treatments were included, with individual patient data (IPD) extracted when available. Visual improvement was defined as a ≥0.3 LogMAR VA reduction. Visual outcomes were compared between patients treated with hyaluronidase or thrombolysis and those who were not, including other therapies and no treatment. Results From 290 manuscripts screened, IPD from 42 studies were included, resulting in 91 patients (93 affected eyes). Mean age was 34.9 years, 96.7% were female. Hyaluronic acid was the most used filler (64%) 93.5% of patients received some treatment; hyaluronidase was administered in 64.1% of cases and intravenous thrombolysis in 19.6%. Baseline and follow-up VA data were available for 76 affected eyes, with significant visual improvement in 36%. Visual improvement rates did not differ significantly between those treated with hyaluronidase and those who were not (63% vs. 37%), nor between those treated with thrombolytics and those who were not (15% vs. 85%). Conclusions No significant differences were observed in hyaluronidase or fibrinolysis use between patients with visual improvement and those with stable or worsening outcomes. IPD for the remaining identified studies have been requested to corresponding authors for further IPD meta-analysis. Conflict of interest Anna Vargas, Aina Sánchez-Quin, Adrián Valls, Marta Balboa, Cristina Del Valle, Carles Vázquez, Bárbara Yugueros, Mònica Millán, Susana Ruiz-Bilbao, Alejandro Bustamante: nothing to disclose Figure 1 - belongs to Methods Figure 2 - belongs to Results

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vargas-Verdaguer et al. (2026) studied this question.

synapsesocial.com/papers/69fd7f4fbfa21ec5bbf07d16https://doi.org/10.1093/esj/aakag023.366
Ask AI
Helpful
Bookmark
Share
View Full Paper